抗小鼠CD8a单克隆抗体(克隆号2.43),体内实验级重组,大鼠IgG2b Kappa | Syd Labs PA007167.r2b
重组抗小鼠CD8a单克隆抗体(克隆号2.43),大鼠IgG2b Kappa,体内实验级(货号:PA007167.r2b)是用哺乳动物细胞生产的重组抗体,从大鼠抗小鼠CD8a单克隆抗体(克隆号:2.43)可变区序列中提取,适用于体外和体内研究,比如体内CD8+T细胞耗竭(清除)。Syd Labs PA007167.r2b不变区为大鼠IgG2b kappa (rIgG2b或r2b),可与重组大鼠IgG2b同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
- 产品参数
- 文献
- More Offers
货号 | PA007167.r2b |
---|---|
产品名称 | 抗小鼠CD8a单克隆抗体(克隆号2.43),体内实验级重组,大鼠IgG2b Kappa | Syd Labs PA007167.r2b |
英文名 | In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Rat IgG2b Kappa |
供货商名称 | Syd Labs, Inc. |
品牌名 | 悉得(Syd Labs) |
别称 | CD8α,T细胞表面糖蛋白CD8α链,CD_抗原CD8a |
概述 | 重组抗小鼠CD8a单克隆抗体是用哺乳动物细胞生产的,从大鼠抗小鼠CD8a单克隆抗体(克隆号:2.43)可变区序列中提取的,适合体外和体内研究。 |
克隆号 | 2.43 |
同种型 | 大鼠 IgG2b, kappa |
特异性 | CD8a |
应用 | 蛋白质印迹、免疫组织化学(IHC)、流式细胞术(FC)和体内CD8+T细胞耗竭(清除) |
抗体形式 | 0.2 μM过滤溶液,1x PBS |
内毒素 | 根据 LAL 方法,≤1 EU每1mg 蛋白质 |
纯度 | >95%(在还原条件下通过SDS-PAGE测定) |
运输 | 体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43),大鼠IgG2b Kappa用冰袋运输。收到后,请立即将其存放在下面建议的温度下。 |
稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C,自收到之日起可保存1个月。 如果保存在-20 至 -70°C,自收到之日起可保存 12个月。 |
注意事项 | PA007167.r2b 悉得(Syd Labs)重组抗小鼠CD8a单克隆抗体是用哺乳动物细胞生产的,从大鼠抗小鼠CD8a单克隆抗体(克隆号:2.43)可变区序列中提取的,适合体外和体内研究。 |
产品咨询 | 悉得(Syd Labs)在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系悉得(Syd Labs)中国代理商。 关于悉得(Syd Labs)产品如果有任何技术或其它问题,欢迎随时联系悉得(Syd Labs)国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理) |
描述
了解更多抗小鼠CD8a单克隆抗体(clone:2.43)引用文献,请查看:抗小鼠CD8a单抗(克隆号2.43)引用文献
抗小鼠CD8a抗体(2.43)参考文献:
1. CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
Lotte K. Kristensen,et al.Theranostics. 2019.PMCID: PMC6857046
“Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of immune-based agents is accelerating and the number of agents in the global immuno-oncology pipeline has grown 60-70% over the past year. However, despite remarkable clinical efficacy in some patients, only few achieve a lasting clinical response. Treatment failure can be attributed to poorly immunogenic tumors that do not attract tumor infiltrating lymphocytes (TILs). Therefore, we developed positron emission tomography (PET) radiotracers for non-invasive detection of CD4+ and CD8a+ TILs in syngeneic mouse tumor models for preclinical studies.Methods: Seven syngeneic mouse tumor models (B16F10, P815, CT26, MC38, Renca, 4T1, Sa1N) were quantified for CD4+ and CD8a+ TILs using flow cytometry and immunohistochemistry (IHC), as well as for tumor growth response to Sym021, a humanized PD-1 antibody cross-reactive with mouse PD-1. Radiotracers were generated from F(ab)’2 fragments of rat-anti-mouse CD4 and CD8a antibodies conjugated to the p-SCN-Bn-Desferrioxamine (SCN-Bn-DFO) chelator and radiolabeled with Zirconium-89 (89Zr-DFO-CD4/89Zr-DFO-CD8a). Tracers were optimized for in vivo PET/CT imaging in CT26 tumor-bearing mice and specificity was evaluated by depletion studies and isotype control imaging. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET/CT imaging was conducted in the panel of syngeneic mouse models prior to immunotherapy with Sym021.Results: Syngeneic tumor models were characterized as “hot” or “cold” according to number of TILs determined by flow cytometry and IHC. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a were successfully generated with a radiochemical purity >99% and immunoreactivity >85%. The optimal imaging time-point was 24 hours post-injection of ~1 MBq tracer with 30 µg non-labeled co-dose. Reduced tumor and spleen uptake of 89Zr-DFO-CD8a was observed in CD8a+ depleted mice and the uptake was comparable with that of isotype control (89Zr-DFO-IgG2b) confirming specificity. PET imaging in syngeneic tumor models revealed a varying maximum tumor-to-heart ratio of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a across tumor types and in-between subjects that correlated with individual response to Sym021 at day 10 relative to start of therapy (p=0.0002 and p=0.0354, respectively). The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018).Conclusion: We developed 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET radiotracers for specific detection and whole-body assessment of CD4+ and CD8a+ status. These radiotracers can be used to phenotype preclinical syngeneic mouse tumor models and to predict response to an immune checkpoint inhibitor. We foresee development of such non-invasive in vivo biomarkers for prediction and evaluation of clinical efficacy of immunotherapeutic agents, such as Sym021.”
2. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice
Guohao Wang,et al.Nat Commun. 2020.PMCID: PMC6954189
“Cancer stem cells (CSCs) may be responsible for treatment resistance, tumor metastasis, and disease recurrence. Here we demonstrate that the Arf1-mediated lipid metabolism sustains cells enriched with CSCs and its ablation induces anti-tumor immune responses in mice. Notably, Arf1 ablation in cancer cells induces mitochondrial defects, endoplasmic-reticulum stress, and the release of damage-associated molecular patterns (DAMPs), which recruit and activate dendritic cells (DCs) at tumor sites. The activated immune system finally elicits antitumor immune surveillance by stimulating T-cell infiltration and activation. Furthermore, TCGA data analysis shows an inverse correlation between Arf1 expression and T-cell infiltration and activation along with patient survival in various human cancers. Our results reveal that Arf1-pathway knockdown not only kills CSCs but also elicits a tumor-specific immune response that converts dying CSCs into a therapeutic vaccine, leading to durable benefits.”
3. Antipodoplanin antibody enhances the antitumor effects of CTLA‐4 blockade against malignant mesothelioma by natural killer cells
Hiroto Yoneda,et al.Cancer Sci. 2024.PMCID: PMC10859607
“Combination immunotherapy with multiple immune checkpoint inhibitors (ICIs) has been approved for various types of malignancies, including malignant pleural mesothelioma (MPM). Podoplanin (PDPN), a transmembrane sialomucin‐like glycoprotein, has been investigated as a diagnostic marker and therapeutic target for MPM. We previously generated and developed a PDPN‐targeting Ab reagent with high Ab‐dependent cellular cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC). However, the effects of anti‐PDPN Abs on various tumor‐infiltrating immune cells and their synergistic effects with ICIs have remained unclear. In the present study, we established a novel rat–mouse chimeric anti‐mouse PDPN IgG2a mAb (PMab‐1‐mG2a) and its core‐fucose‐deficient Ab (PMab‐1‐mG2a‐f) to address these limitations. We identified the ADCC and CDC activity of PMab‐1‐mG2a‐f against the PDPN‐expressing mesothelioma cell line AB1‐HA. The antitumor effect of monotherapy with PMab‐1‐mG2a‐f was not sufficient to overcome tumor progression in AB1‐HA‐bearing immunocompetent mice. However, PMab‐1‐mG2a‐f enhanced the antitumor effects of CTLA‐4 blockade. Combination therapy with anti‐PDPN Ab and anti‐CTLA‐4 Ab increased tumor‐infiltrating natural killer (NK) cells. The depletion of NK cells inhibited the synergistic effects of PMab‐1‐mG2a‐f and CTLA‐4 blockade in vivo. These findings indicated the essential role of NK cells in novel combination immunotherapy targeting PDPN and shed light on the therapeutic strategy in advanced MPM.”
悉得(Syd Labs)抗小鼠CD8a重组抗体(克隆号2.43),大鼠IgG2b Kappa(货号:PA007167.r2b)推荐同型对照抗体:
悉得(Syd Labs)提供以下体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43):
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43),大鼠IgG2b Kappa
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43),小鼠IgG2a Kappa
悉得(Syd Labs)还提供以下重组抗小鼠CD8a单克隆抗体:
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号YTS 169.4),大鼠IgG2b Kappa
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号YTS 169.4),小鼠IgG2a Kappa
体内实验级重组抗小鼠CD8a单克隆抗体(克隆号YTS 105.18),大鼠IgG2a Kappa
请记住我们的产品信息: 体内实验级重组抗小鼠CD8a单克隆抗体(克隆号2.43),大鼠IgG2b Kappa: PA007167.r2b Syd Labs In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Rat IgG2b Kappa。